Clicky

Cannabis

THC metabolites and active compounds: Why laboratory terms are not interchangeable

October 8, 2026
9 Min Read

By HealthDataConsortium.org Research Team

The word “THC” shows up on lab documents attached to at least four different compounds, and only some of them act on the brain. That is the short version of why laboratory terms are not interchangeable. This guide separates the compounds, shows where the two concepts, “metabolite” and “active compound,” part ways, and then applies the difference to three documents a reader might actually be handed.

The Short Answer

A metabolite is something the body makes from THC. An active compound affects the brain. The two lists overlap, but they aren’t the same. THC itself and one of its first metabolites, 11-hydroxy-THC (11-OH-THC), are described in the pharmacology literature as active. Metabolite-standard urine tests are designed to detect 11-nor-9-carboxy-THC (THC-COOH), which is described as inactive.

So a result reading “positive for a THC metabolite” reports on an inactive end product. A urine result like that indicates exposure at some point. It does not show when, how much, or whether the person is impaired.

Four Names That Get Mixed Up

Public health pages describe THC as the substance mainly responsible for the effects of marijuana on a person’s mental state (NCCIH) and as the component that produces the “high” (FDA). Neither page walks through metabolites, so the pharmacology below comes from a 2007 pharmacokinetics review by Marilyn Huestis in Chemistry & Biodiversity. Here is how the four names line up.

  • THC (Δ9-THC), the parent compound. This is the psychoactive cannabinoid people usually mean by “THC.”
  • THCA, the plant-side acid form. The Huestis review explains that THC sits in the plant largely as carboxylic acids, which lose a carboxyl group readily when heated and become THC. Product lab reports list THCA beside THC, and our guide to reading cannabis lab reports covers how to read those lines.
  • 11-OH-THC, the first metabolite. Liver enzymes convert THC into 11-OH-THC, which the review calls equipotent with THC. In a study it cites, equal doses of the two produced equal psychoactive effects, although the effects were felt faster after 11-OH-THC.
  • THC-COOH, the inactive end product. The body oxidizes 11-OH-THC into THC-COOH, which the review calls inactive. Its glucuronide conjugate is the main metabolite found in urine, and the American College of Medical Toxicology (ACMT) notes that clinical urine immunoassays use antibodies directed against THC-COOH.

The takeaway: “metabolite” and “inactive” are not synonyms. 11-OH-THC is a metabolite and is active. THC-COOH is a metabolite and is inactive. A single word like “metabolite” hides that split.

A Naming Trap in the Federal Cutoff Tables

The same letters can point at opposite ends of the pipeline. In the U.S. Department of Transportation’s urine table (49 CFR 40.85), the marijuana row is labeled “Marijuana metabolites (THCA),” with a 50 ng/mL initial cutoff and a 15 ng/mL confirmatory cutoff. THCA is the urinary target. It is not the plant-side acid that a product lab report calls THCA.

The Department of Health and Human Services (HHS) uses yet another label. Its annual notice of authorized federal workplace testing panels, issued in March 2026, reports the urine analyte under the abbreviation Δ9THCC, defined as Δ-9-tetrahydrocannabinol-9-carboxylic acid, at the same 50 and 15 ng/mL cutoffs. The ACMT position statement, in clinical language, describes the HHS positive as THC-COOH above 15 ng/mL.

Three documents therefore use three labels (THCA, Δ9THCC and THC-COOH) for what the cutoff tables and the clinical statement treat as the same urinary target. Reading any of them correctly means checking which compound the label names. Our explainer on cutoffs and recent impairment covers how cutoffs work and why they are administrative lines rather than measures of effect, so this guide does not repeat it.

Where the Two Concepts Diverge

  • Activity. THC and 11-OH-THC are described as active. THC-COOH is described as inactive.
  • Timing in blood. In a small controlled smoking study summarized in the review, plasma THC fell to 5 ng/mL or less within about two hours. Mean detection times for 11-OH-THC were 4.5 hours after a lower-dose cigarette and 11.2 hours after a higher-dose one. THC-COOH was detected for a mean of 84 and 152 hours after the same two doses. Those figures come from one study’s doses, volunteers, and assay limits. They show the shape of the gap, not a personal timeline.
  • Route of use. After smoking, plasma 11-OH-THC runs around a tenth of THC levels. After oral dosing, it is higher, and one oral study reported 11-OH-THC above THC. For edibles, then, the active metabolite plays a larger role. Our article on edible timing covers why the effects arrive late.
  • Specimen type. Urine tests aim at THC-COOH. The HHS oral fluid panel instead names Δ9THC, with an initial cutoff of 4 ng/mL and a confirmatory cutoff of 2 ng/mL for federal agency specimens. The Huestis review says oral fluid assays work best when aimed at THC itself, because the mouth is exposed to THC directly during smoking.
  • What a result supports. A urine metabolite result indirectly indicates that THC was present in the body. ACMT says it does not identify route, source, timing, dose, or impairment. The Huestis review says a positive urine test indicates only that exposure occurred.

Worked Comparison: Three Documents, Three Different Questions

Picture a reader sorting through three pieces of paper that all mention “THC.” This illustrates reading documents, not a story about a real person or a prediction for anyone.

Document one: a product lab report

  • What it names: THCA and THC in a tested sample of a product batch.
  • What it can support: what the lab found in that sample.
  • What it cannot support: anything about what happens in a person’s body, or about any drug test result. The THCA here is the plant-side acid.

Document two: a confirmed urine result

  • What it names: a marijuana metabolite at or above 15 ng/mL, labeled THCA in the DOT table, Δ9THCC in the HHS notice, or THC-COOH in clinical toxicology.
  • What it can support: that THC entered the body before the specimen was collected.
  • What it cannot support: timing, amount, route, source, or impairment. The analyte is the inactive end product, and it can stay detectable far longer than THC’s effects last. ACMT says that in chronic heavy users, it may remain detectable for a month or longer.

Document three: an oral fluid result

  • What it names: Δ9THC, the parent compound.
  • What it can support: that THC itself was found in the mouth. The Huestis review says detection times in oral fluid are shorter than in urine and more indicative of recent use.
  • What it cannot support: impairment. The same review says wide variation between and within individuals makes oral fluid concentrations unreliable indicators of impairment.

What the comparison shows

All three documents say “THC” somewhere, yet they measure different compounds in different places, and only the third measures the parent compound. A headline like “tested positive for THC” cannot tell you which of the three situations it describes.

“Active” is not “impaired,” either. The review notes that 11-OH-THC may appear in the urine of chronic users beyond the period of effects and performance impairment, and that estimating time of use from urinary THC or 11-OH-THC needs more research. Presence of a compound, even an active one, answers a different question than whether someone is affected right now. Our article on cannabis and driving research shows how public health agencies treat that gap.

Questions That Cut Through the Terminology

  • Which compound does the result name: THC, THCA, 11-OH-THC, or THC-COOH (also written THCA or Δ9THCC in federal tables)?
  • Which specimen was tested: urine, oral fluid, blood or something else?
  • Which cutoff applied, and was the result confirmed by a second method?
  • Who reviews the result, and what program’s rules apply?

What This Article Cannot Tell You

  • It cannot interpret your own result, estimate how long any compound stays detectable for you, or say what a result means for your job, license or legal situation.
  • The time-course figures come from a 2007 review that summarizes controlled studies from earlier decades. The NCCIH and FDA pages cited for THC’s role were last updated in 2019 and 2020 and do not cover metabolites.
  • It gives no advice on affecting a test outcome, and no waiting period before any activity.
  • It has not been clinically or peer reviewed. HealthDataConsortium.org is an independent publication whose contributors are researchers, not licensed clinicians. See the site’s Medical Disclaimer.

Who Should Get Professional Advice

If a result affects your employment, license, custody or legal status, speak with the program’s Medical Review Officer or a licensed attorney. If you use cannabis for a health reason, take other medicines, or have questions about your own health, talk with your clinician or pharmacist. This article is educational and is not medical or legal advice.

Related Reading on HealthDataConsortium.org

Sources Checked

This article contains no affiliate links and no product recommendations. Site-wide disclosures are on the Methodology & Disclosures page.

Related guides